Tg Therapeutics (TGTX) Finished Goods (2023 - 2025)

Tg Therapeutics' Finished Goods history runs 3 years deep, the most recent figure standing at $21.1 million for Q3 2025.

• In Q3 2025, Finished Goods rose 164.86% year-over-year to $21.1 million; the TTM figure through Sep 2025 stood at $21.1 million (up 164.86% YoY), while the FY2024 annual figure was $13.9 million, up 597.25% from the prior year.
• Finished Goods for Q3 2025 stood at $21.1 million, down from $21.8 million in the prior quarter.
• The five-year high for Finished Goods was $21.8 million in Q2 2025, with the low at $52000.0 in Q1 2023.
• The 3-year median for Finished Goods is $2.0 million (2023), against an average of $7.5 million.
• Peak annual rise in Finished Goods reached 3559.62% in 2024, while the deepest fall reached 145.07% in 2024.
• Tg Therapeutics' Finished Goods stood at $2.0 million in 2023, then soared by 597.25% to $13.9 million in 2024, then surged by 51.3% to $21.1 million in 2025.
• Business Quant data shows TGTX's Finished Goods at $21.1 million in Q3 2025, $21.8 million in Q2 2025, and $10.7 million in Q1 2025.